Bristol Myers nabs long-sought FDA nod for Celgene’s MS drug ozanimod, but pandemic delays launch

Bristol Myers Squibb’s $74 billion acquisition of Celgene last year hinged on a few of Celgene‚Äôs late-stage pipeline hopefuls, including multiple sclerosis treatment ozanimod. Now that the drug has finally reached the finish line, it will face a range of challenges, starting with a delayed launch due to COVID-19.

Leave a Reply

Your email address will not be published. Required fields are marked *